公开(公告)号：US10744188B2

公开(公告)日：2020-08-18

申请号：US15958308

申请日：2018-04-20

申请人： Waitaki Biosciences

发明人： Craig Lachlan McIntosh ,  Susan Finderup ,  Harold Garthwaite

IPC分类号： A61K38/39 ,  A23L33/16 ,  A23L33/17 ,  A61K9/14 ,  A61K33/42 ,  A61K35/32

摘要： An improved manufacturing process produces microcrystalline hydroxyapatite with sustained gradual calcium release that avoids spiking in blood calcium levels. Although the improved material did not cause significant elevation of blood calcium, it was just as effective in promoting bone mineralization as conventional calcium supplements. In addition, the material has much higher levels of bone growth factors as compared to prior hydroxyapatite products.

公开(公告)号：US09974841B2

公开(公告)日：2018-05-22

申请号：US14916695

申请日：2014-09-04

申请人： Waitaki Biosciences

发明人： Craig Lachlan McIntosh ,  Susan Finderup ,  Harold Garthwaite

IPC分类号： A61K38/39 ,  A23L33/16 ,  A61K9/14 ,  A61K33/42 ,  A23L33/17 ,  A61K35/32

CPC分类号： A61K38/39 ,  A23L33/16 ,  A23L33/17 ,  A23V2002/00 ,  A61K9/14 ,  A61K33/42 ,  A61K35/32 ,  A23V2200/306 ,  A23V2250/1578

摘要： An improved manufacturing process produces microcrystalline hydroxyapatrte with sustained gradual calcium release that avoids spiking in blood calcium levels. Although the improved material did not cause significant elevation of blood calcium, it was just as effective in promoting bone mineralization as conventional calcium supplements. In addition, the material has much higher levels of bone growth factors as compared to prior hydroxyapatite products.

公开(公告)号：US20180236039A1

公开(公告)日：2018-08-23

申请号：US15958308

申请日：2018-04-20

申请人： Waitaki Biosciences

发明人： Craig Lachlan McIntosh ,  Susan Finderup ,  Harold Garthwaite

IPC分类号： A61K38/39 ,  A23L33/17 ,  A61K33/42 ,  A61K9/14 ,  A23L33/16

摘要： An improved manufacturing process produces microcrystalline hydroxyapatite with sustained gradual calcium release that avoids spiking in blood calcium levels. Although the improved material did not cause significant elevation of blood calcium, it was just as effective in promoting bone mineralization as conventional calcium supplements. In addition, the material has much higher levels of bone growth factors as compared to prior hydroxyapatite products.

公开(公告)号：US20160228517A1

公开(公告)日：2016-08-11

申请号：US14916695

申请日：2014-09-04

申请人： WAITAKI BIOSCIENCES

发明人： Craig Lachlan McIntosh ,  Susan Finderup ,  Harold Garthwaite

IPC分类号： A61K38/39 ,  A61K9/14 ,  A61K33/42

CPC分类号： A61K38/39 ,  A23L33/16 ,  A23L33/17 ,  A23V2002/00 ,  A61K9/14 ,  A61K33/42 ,  A61K35/32 ,  A23V2200/306 ,  A23V2250/1578

摘要： An improved manufacturing process produces microcrystalline hydroxyapatrte with sustained gradual calcium release that avoids spiking in blood calcium levels. Although the improved material did not cause significant elevation of blood calcium, it was just as effective in promoting bone mineralization as conventional calcium supplements. In addition, the material has much higher levels of bone growth factors as compared to prior hydroxyapatite products.

摘要翻译： 改进的制造过程产生具有持续的逐渐钙释放的微晶羟基磷灰石，其避免血钙水平的尖峰。 虽然改进的材料没有引起血钙的显着升高，但与常规的钙补充剂一样有利于促进骨矿化。 此外，与以前的羟基磷灰石产品相比，该材料具有高得多的骨生长因子水平。